Literature DB >> 30346562

Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers.

Nicole P Lindsey1, Kalanthe A Horiuchi1, Corey Fulton1, Amanda J Panella1, Olga I Kosoy1, Jason O Velez1, Elizabeth R Krow-Lucal1, Marc Fischer1, J Erin Staples1.   

Abstract

Background: Few studies have assessed the duration of humoral immunity following yellow fever (YF) vaccination in a non-endemic population. We evaluated seropositivity among US resident travellers based on time post-vaccination.
Methods: We identified serum samples from US travellers with YF virus-specific plaque reduction neutralization testing (PRNT) performed at CDC from 1988 to 2016. Analyses were conducted to assess the effect of time since vaccination on neutralizing antibody titer counts.
Results: Among 234 travellers who had neutralizing antibody testing performed on a specimen obtained ≥1 month after vaccination, 13 received multiple YF vaccinations and 221 had one dose of YF vaccine reported. All 13 who received more than one dose of YF vaccine had a positive PRNT regardless of the amount time since most recent vaccination. Among the 221 travellers with one reported dose of YF vaccine, 155 (70%) were vaccinated within 10 years (range 1 month-9 years) and 66 (30%) were vaccinated ≥10 years (range 10-53 years) prior to serum collection. Among the 155 individuals vaccinated, <10 years prior to serum collection, 146 (94%) had a positive PRNT compared with 82% (54/66) of individuals vaccinated ≥10 years prior to serum collection (P = 0.01). Post-vaccination PRNT titers showed a time-dependent decrease. Individuals with immunocompromising conditions were less likely to have a positive PRNT (77%) compared with those who were not immunocompromised (92%; P = 0.04).
Conclusion: Although the percentage of vaccinees with a positive PRNT and antibody titers decreased over time, a single dose of YF vaccine provided long-lasting protection in the majority of US travellers. A booster dose could be considered for certain travellers who are planning travel to a high risk area based on immune competence and time since vaccination.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30346562      PMCID: PMC7135922          DOI: 10.1093/jtm/tay108

Source DB:  PubMed          Journal:  J Travel Med        ISSN: 1195-1982            Impact factor:   8.490


  34 in total

1.  Neutralizing and haemagglutination-inhibiting antibodies to yellow fever 17 years after vaccination with 17D vaccine.

Authors:  H GROOT; R B RIBERIRO
Journal:  Bull World Health Organ       Date:  1962       Impact factor: 9.408

2.  [Duration of immunity after yellow fever vaccination].

Authors:  G COURTOIS
Journal:  Ann Soc Belg Med Trop (1920)       Date:  1954-01-28

3.  Yellow fever virus: Increasing imported cases in China.

Authors:  Lifang Wang; Pei Zhou; Xingliang Fu; Yun Zheng; San Huang; Bo Fang; Guihong Zhang; Kun Jia; Shoujun Li
Journal:  J Infect       Date:  2016-07-13       Impact factor: 6.072

4.  2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.

Authors:  Lorry G Rubin; Myron J Levin; Per Ljungman; E Graham Davies; Robin Avery; Marcie Tomblyn; Athos Bousvaros; Shireesha Dhanireddy; Lillian Sung; Harry Keyserling; Insoo Kang
Journal:  Clin Infect Dis       Date:  2013-12-04       Impact factor: 9.079

Review 5.  Insights into human CD8(+) T-cell memory using the yellow fever and smallpox vaccines.

Authors:  Rafi Ahmed; Rama S Akondy
Journal:  Immunol Cell Biol       Date:  2011-02-08       Impact factor: 5.126

6.  Isolation and characterization of wild type yellow fever virus in cases temporally associated with 17DD vaccination during an outbreak of yellow fever in Brazil.

Authors:  Ana Maria Bispo de Filippis; Rita Maria Ribeiro Nogueira; Alfredo Verlangieri Jabor; Hermann G Schatzmayr; Janice Coelho Oliveira; Sonia C Machado Dinis; Ricardo Galler
Journal:  Vaccine       Date:  2004-03-12       Impact factor: 3.641

7.  Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil.

Authors:  Andréa Barbosa de Melo; Maria da Paz C da Silva; Maria Cecília F Magalhães; Laura Helena Vega Gonzales Gil; Eduardo M Freese de Carvalho; Ulisses M Braga-Neto; Giovani Rota Bertani; Ernesto T A Marques; Marli Tenório Cordeiro
Journal:  Am J Trop Med Hyg       Date:  2011-10       Impact factor: 2.345

8.  Yellow Fever Vaccine Booster Doses: Recommendations of the Advisory Committee on Immunization Practices, 2015.

Authors:  J Erin Staples; Joseph A Bocchini; Lorry Rubin; Marc Fischer
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-06-19       Impact factor: 17.586

9.  Increased risk of yellow fever infections among unvaccinated European travellers due to ongoing outbreak in Brazil, July 2017 to March 2018.

Authors:  Céline M Gossner; Joana M Haussig; Chiara de Bellegarde de Saint Lary; Kaja Kaasik Aaslav; Patricia Schlagenhauf; Bertrand Sudre
Journal:  Euro Surveill       Date:  2018-03

10.  Booster dose after 10 years is recommended following 17DD-YF primary vaccination.

Authors:  Ana Carolina Campi-Azevedo; Christiane Costa-Pereira; Lis R Antonelli; Cristina T Fonseca; Andréa Teixeira-Carvalho; Gabriela Villela-Rezende; Raiany A Santos; Maurício A Batista; Fernanda M Campos; Luiza Pacheco-Porto; Otoni A Melo Júnior; Débora M S H Hossell; Jordana G Coelho-dos-Reis; Vanessa Peruhype-Magalhães; Matheus F Costa-Silva; Jaquelline G de Oliveira; Roberto H Farias; Tatiana G Noronha; Jandira A Lemos; Vanessa dos R von Doellinger; Marisol Simões; Mirian M de Souza; Luiz C Malaquias; Harold R Persi; Jorge M Pereira; José A Martins; Marcos Dornelas-Ribeiro; Aline de A Vinhas; Tatiane R Alves; Maria de L Maia; Marcos da S Freire; Reinaldo de M Martins; Akira Homma; Alessandro P M Romano; Carla M Domingues; Pedro L Tauil; Pedro F Vasconcelos; Maria Rios; Iramaya R Caldas; Luiz A Camacho; Olindo Assis Martins-Filho
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

View more
  12 in total

Review 1.  Yellow Fever in Travelers.

Authors:  Annelies Wilder-Smith
Journal:  Curr Infect Dis Rep       Date:  2019-10-31       Impact factor: 3.725

Review 2.  Role of Multivalency and Antigenic Threshold in Generating Protective Antibody Responses.

Authors:  Mark K Slifka; Ian J Amanna
Journal:  Front Immunol       Date:  2019-05-01       Impact factor: 8.786

3.  Short-Lived Immunity After 17DD Yellow Fever Single Dose Indicates That Booster Vaccination May Be Required to Guarantee Protective Immunity in Children.

Authors:  Ana Carolina Campi-Azevedo; Laise Rodrigues Reis; Vanessa Peruhype-Magalhães; Jordana Grazziela Coelho-Dos-Reis; Lis Ribeiro Antonelli; Cristina Toscano Fonseca; Christiane Costa-Pereira; Elaine Maria Souza-Fagundes; Ismael Artur da Costa-Rocha; Juliana Vaz de Melo Mambrini; Jandira Aparecida Campos Lemos; José Geraldo Leite Ribeiro; Iramaya Rodrigues Caldas; Luiz Antônio Bastos Camacho; Maria de Lourdes de Sousa Maia; Tatiana Guimarães de Noronha; Sheila Maria Barbosa de Lima; Marisol Simões; Marcos da Silva Freire; Reinaldo de Menezes Martins; Akira Homma; Pedro Luiz Tauil; Pedro Fernando Costa Vasconcelos; Alessandro Pecego Martins Romano; Carla Magda Domingues; Andréa Teixeira-Carvalho; Olindo Assis Martins-Filho
Journal:  Front Immunol       Date:  2019-09-26       Impact factor: 7.561

Review 4.  What Constitutes Protective Immunity Following Yellow Fever Vaccination?

Authors:  Jolynne Mokaya; Derick Kimathi; Teresa Lambe; George M Warimwe
Journal:  Vaccines (Basel)       Date:  2021-06-18

5.  Persistence of Neutralizing Antibody Responses Among Yellow Fever Virus 17D Vaccinees Living in a Nonendemic Setting.

Authors:  Bettie W Kareko; Brian L Booty; Chad D Nix; Zoe L Lyski; Mark K Slifka; Ian J Amanna; William B Messer
Journal:  J Infect Dis       Date:  2020-06-11       Impact factor: 7.759

6.  Dynamic changes in circulating T follicular helper cell composition predict neutralising antibody responses after yellow fever vaccination.

Authors:  Johanna E Huber; Julia Ahlfeld; Magdalena K Scheck; Magdalena Zaucha; Klaus Witter; Lisa Lehmann; Hadi Karimzadeh; Michael Pritsch; Michael Hoelscher; Frank von Sonnenburg; Andrea Dick; Giovanna Barba-Spaeth; Anne B Krug; Simon Rothenfußer; Dirk Baumjohann
Journal:  Clin Transl Immunology       Date:  2020-05-13

Review 7.  Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection.

Authors:  J Erin Staples; Alan D T Barrett; Annelies Wilder-Smith; Joachim Hombach
Journal:  NPJ Vaccines       Date:  2020-07-06       Impact factor: 7.344

8.  Zika virus infection in pregnancy: Establishing a case definition for clinical research on pregnant women with rash in an active transmission setting.

Authors:  Ricardo Arraes de Alencar Ximenes; Demócrito de Barros Miranda-Filho; Elizabeth B Brickley; Ulisses Ramos Montarroyos; Celina Maria Turchi Martelli; Thalia Velho Barreto de Araújo; Laura C Rodrigues; Maria de Fatima Pessoa Militão de Albuquerque; Wayner Vieira de Souza; Priscila Mayrelle da Silva Castanha; Rafael F O França; Rafael Dhália; Ernesto T A Marques
Journal:  PLoS Negl Trop Dis       Date:  2019-10-07

9.  Longitudinal dynamics of the human B cell response to the yellow fever 17D vaccine.

Authors:  Anna Z Wec; Denise Haslwanter; Yasmina N Abdiche; Laila Shehata; Nuria Pedreño-Lopez; Crystal L Moyer; Zachary A Bornholdt; Asparouh Lilov; Juergen H Nett; Rohit K Jangra; Michael Brown; David I Watkins; Clas Ahlm; Mattias N Forsell; Félix A Rey; Giovanna Barba-Spaeth; Kartik Chandran; Laura M Walker
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-09       Impact factor: 11.205

10.  Limited evolution of the yellow fever virus 17d in a mouse infection model.

Authors:  Dieudonné Buh Kum; Niraj Mishra; Bram Vrancken; Hendrik Jan Thibaut; Annelies Wilder-Smith; Philippe Lemey; Johan Neyts; Kai Dallmeier
Journal:  Emerg Microbes Infect       Date:  2019       Impact factor: 7.163

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.